Comment
Author: Admin | 2025-04-28
Price of the DIN of the comparable listed tablet or capsule. 3.4.3 Extemporaneous mixtures: External use The following mixtures are eligible under NIHB without prior approval: mixtures for external use with corresponding open benefit pseudo-DINs mixture that are a combination of 2 or more open benefit external use products only (the use of non-medicinal bases require prior approval) mixtures that are a combination of one or more external use products listed as open benefit on the Drug Benefit List, available on the Express Scripts Canada NIHB provider and client website, and one or more of the following: urea, menthol or camphor or mixtures that are a combination of ingredients as outlined below in section 3.4.3.1 Table 4: Eligible ingredient combinations for external mixtures Note: The strength of hydrocortisone in finished products must be ≥0.5% (excluding hydrocortisone valerate). 3.4.3.1 Table 4: Eligible ingredient combinations for external mixtures 1 or more eligible ingredients AND 1 or more external use product listed as open benefit on the Drug Benefit List, (available on the Express Scripts Canada NIHB provider and client website) or one or more non-medicinal eligible base Note: In situations where a generic or house brand of an eligible base exists at an equal or lower cost, this product may be used in lieu of the listed brand-name bases. +/- 1 or more ingredients *no minimum concentration required anthralin betamethasone powder clindamycin powder clotrimazole powder coal tar/LCD erythromycin powder hydrocortisone powder (in strengths equal to or greater than 0.5%) ketoconazole powder lidocaine powder metronidazole powder miconazole powder nifedipine powder nystatin powder salicylic acid powder sulfur powder Aquaphor CeraVe cream/lotion Cetaphil Cliniderm cocoa butter cold cream compound tincture of benzoin (Friar's balsam) Dermabase Dilusol Eucerin Glaxal Base Ihle's Paste lanolin Lassar's Paste Lubriderm mediderm mineral oil petrolatum (Vaseline) cream/lotion containing a maximum of 22% urea zinc oxide creams/ointments Camphor* Menthol* Urea* 3.4.4 Extemporaneous mixtures: Topical non-steroidal anti-inflammatory (NSAID) in transdermal base Coverage is provided for compounded topical non-steroidal anti-inflammatory as per below in section 3.4.4.1 Table 5: NIHB coverage of compounded topical non-steroidal anti-inflammatories. These products are listed as an open benefit. No
Add Comment